share_log

Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target

Benzinga ·  22:46

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment